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Genetic and molecular changes in ovarian cancer
Robert L Hollis, Charlie Gourley
Edinburgh Cancer  Research UK Centre,  MRC Institute of  Genetics  and Molecular  Medicine,  University  of  Edinburgh,
Edinburgh, EH4 2XR, UK
 
ABSTRACT Epithelial ovarian cancer represents the most lethal gynecological malignancy in the developed world, and can be divided into five
main histological subtypes: high grade serous, endometrioid, clear cell, mucinous and low grade serous. These subtypes represent
distinct disease entities, both clinically and at the molecular level. Molecular analysis has revealed significant genetic heterogeneity
in ovarian cancer, particularly within the high grade serous subtype. As such, this subtype has been the focus of much research
effort to date,  revealing molecular subgroups at both the genomic and transcriptomic level that have clinical implications.
However, stratification of ovarian cancer patients based on the underlying biology of their disease remains in its infancy. Here, we
summarize the molecular changes that characterize the five main ovarian cancer subtypes, highlight potential opportunities for
targeted therapeutic intervention and outline priorities for future research.
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Introduction
Ovarian cancer (OC) represents the most lethal gynecological
malignancy in the developed world, with over 21,000 cases
diagnosed, accounting for over 14,000 deaths per year in the
United States alone1. The vast majority of ovarian cancers are
of epithelial origin, which are typically diagnosed at advanced
stage.  The current  standard of  care  for  epithelial  ovarian
cancer comprises maximal cytoreductive surgical resection
and platinum-taxane combination chemotherapy2.
A number of clinical parameters influence outcome in OC
patients. Age at diagnosis, FIGO stage, disease grade and the
presence  of  ascites  are  independent  factors  affecting
progression-free-survival (PFS) and overall survival (OS) in
OC  patients3-5.  Suboptimal  debulking  surgery,  leaving
macroscopic residual disease, also has a significant impact on
patient survival6.
Epithelial OC has historically been grouped according to
histology and is currently divided into five main subtypes:
high grade serous (HGS), endometrioid, clear cell (CC), low
grade serous (LGS) and mucinous OC7 (Table 1). It is now
recognized that these subtypes have distinct developmental
origins: HGS OC predominantly arises from the epithelium
of the distal fallopian tubes, while CC and endometrioid OC
are associated with endometriosis8-16. LGS OC is thought to
progress in a step-wise fashion from serous cystadenoma or
adenofibroma to serous borderline tumor, and then to LGS
OC17. These histological subtypes display distinct molecular
landscapes at both the genomic and transcriptomic level9,18-
20.  In  the  face  of  mounting  evidence  for  the  discrete
developmental  origins and molecular pathogenesis  of  OC
subtypes, there is now a growing appreciation that these five
histologically-defined  groups  represent  separate  disease
entities, and that there is a need for stratification in both the
clinical and research setting7,21.
In  keeping  with  the  argument  that  they  are  different
diseases,  these  subtypes  display  different  levels  of
chemosensitivity.  CC,  mucinous  and  LGS OC are  highly
platinum resistant, while HGS OC is often platinum sensitive
in the first-line setting22-24. Despite the tendency to display
therapy  resistance,  LGS  OC  is  associated  with  superior
clinical  outcome  compared  to  HGS,  displaying  a  more
indolent disease course, even when diagnosed at advanced
stage25.  Endometrioid  and  CC OC also  display  generally
superior clinical outcome when compared to HGS, which is
likely due to their propensity for diagnosis at earlier stage22,26-30.
However, histological subtype alone does not account for
the  significant  clinical  heterogeneity  seen in  OC.  Indeed,
HGS OC patients matched for disease grade and stage show
differential  therapy  sensitivity,  PFS  and  OS,  strongly
  
Correspondence to: Charlie Gourley
E-mail: charlie.gourley@ed.ac.uk
Received March 2, 2016; accepted April 11, 2016.
Available at www.cancerbiomed.org
Copyright © 2016 by Cancer Biology & Medicine
Cancer Biol Med 2016. doi: 10.20892/j.issn.2095-3941.2016.0024
implicating a molecular basis for the clinical heterogeneity
within  these  histologically-defined  groups31.  Extensive
molecular characterization of HGS OC has therefore been
undertaken to identify subgroups defined by their genomic
and transcriptomic characteristics, in the hope of finding a
molecular  basis  for  differential  clinical  outcome  and  to
identify opportunities for targeted therapeutic intervention
and treatment stratification.
Approximately one fifth of OC is associated with inherited
pathogenic variants in the germline, commonly in BRCA1 or
BRCA2  which  account  for  around  75%  of  hereditary
disease32,33. The molecular and clinical implications of these
defects are discussed below. While BRCA-associated disease
is the most common form of hereditary OC, defects in other
DNA repair associated genes have also been identified. These
include genes that, like BRCA1 and BRCA2, are involved with
double  stranded  DNA  repair,  such  as  BARD1,  CHEK2,
RAD51, PALB2 and BRIP133-36.
Lynch  syndrome,  caused  by  inherited  defects  in  genes
involved in single stranded mismatch DNA repair (MMR),
most  commonly  predisposes  individuals  to  bowel  and
endometrial  malignancy,  but  these  patients  are  also  at
increased risk of OC37,38. The most commonly affected genes
in this syndrome are MLH1, MSH2, MSH6 and PMS2, and
Lynch syndrome patients account for around 10%-15% of
hereditary OC39.
Li-Fraumeni  syndrome,  caused  by  an  inherited  TP53
mutation,  accounts  for  much of  the remaining identified
hereditary OC cases (around 3%)33.
Genetic and molecular changes in
HGS OC
HGS OC accounts for approximately 70% of OC7. Of these,
only  a  minority  are  confined  to  the  ovary  at  diagnosis.
Despite  response  rates  to  first-line  platinum-based
chemotherapy  of  around  80%,  the  majority  of  patients
experience disease recurrence which accrues resistance to
platinum, and prognosis for advanced stage disease remains
poor with a five-year survival of around 30%40.
DNA sequence
The  most  frequent  molecular  defect  in  HGS  OC  at  the
genomic level is almost ubiquitous TP53 mutation18,41,42. The
majority of these mutations are missense variants, however
around  30%  are  frameshift,  nonsense  or  splice  junction
variants  which  result  in  complete  loss  of  p53  protein,
commonly referred to as 'p53 nulls'43. Despite this canonical
cancer-associated defect, HGS OC does not generally display
the classical activating oncogenic mutations typical of other
solid  tumor  types18,44.  Instead,  extensive  somatic  copy
number  changes  -  rooted in  chromosome instability  and
defective DNA repair - scar the genomic landscape18,45.
Around  half  of  HGS  OC  have  identifiable  germline,
somatic  or  epigenetic  defects  in  the  homologous
recombination  DNA repair  (HRR)  pathway,  the  flagship
defects  being  germline  or  somatic  BRCA1  or  BRCA2
mutations which together account for approximately 20% of
cases46 (Figure 1). Around 8% and 6% of HGS OC patients
harbor germline BRCA1  and BRCA2  defects,  respectively,
Table 1   Characteristic of the five main histological subtypes of OC
HGS Endometrioid Clear cell Mucinous LGS
Approximate proportion
of OC cases
70% 10% 10% <5% <5%
Overall prognosis Poor Favourable Intermediate Intermediate Intermediate
Tissue of origin /
precursor lesion
Distal fallopian
epithelium
Endometriosis Endometriosis Poorly defined Serous borderline
tumor
Intrinsic chemosensitivity High High Low Low Low
Associated hereditary
syndromes
Germline BRCA1/2 Lynch syndrome Lynch syndrome
Typical stage at diagnosis 80% advanced stage 50% early stage 60% early stage 80% early stage Typically advanced
stage
Frequent molecular
abnormalities
Chromosome instability
BRCA1, BRCA2 TP53, NF1,
RB1 CCNE1 amp.
PTEN, PIK3CA,
ARID1A, CTNNB1
PTEN, PIK3CA,
ARID1A,
chr20q13.2, amp
KRAS, HER2 amp KRAS, BRAF
Early stage: FIGO stage I or II; advanced stage: FIGO stage III-IV; amp: amplification
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while somatic changes in each occur in approximately 4%
and 3% of cases18,47,48. HRR-deficiency provides a rationale
for the use of PARP inhibitors (PARPi), inducing synthetic
lethality via inhibition of DNA single stranded break repair
mechanisms and induction of error-prone non-homologous
end joining (NHEJ) in HRR-deficient tumor cells49. These
agents  have proven clinically  effective,  particularly  in the
BRCA-mutated HRR-deficient population50,51.
Historically, analyses have grouped BRCA1- and BRCA2-
defective patients together and have demonstrated improved
sensitivity to cytotoxic chemotherapies and superior clinical
outcome in this group, despite their propensity to develop
visceral metastases and to present with HGS histology46,52-56.
However,  it  has  recently  emerged  that  the  clinical
implications of BRCA1 and BRCA2 defects are distinct, with
BRCA1  carriers  experiencing  only  short-term  survival
advantage  while  the  survival  benefit  in  BRCA2  carriers
persists 10 years from diagnosis57. Notably, BRCA1 can also
be epigenetically inactivated, with around 11% of HGS OC
showing BRCA1 promoter hypermethylation18,58. However,
BRCA1-methylated patients are not thought to experience
the same survival benefit as those with other BRCA defects,
and may even experience reduced disease-free intervals and
inferior OS59.
Structural and copy number changes
HGS OC is characterized by substantial genetic heterogeneity
and  these  tumors  display  large  numbers  of  structural
genomic  changes18,45,60.  As  such,  identifying  structural
variants that represent driver events in tumorigenesis  has
presented a significant challenge. Such structural changes are
now  known  to  be  an  important  mechanism  of  tumor
suppressor  gene  inactivation  in  HGS  OC,  most  notably
affecting the RB and MAPK/PI3K signalling pathways18,45.
The  TCGA  investigators  identified  defects  in  RB1  (8%
deletion, 2% mutation), NF1  (8% deletion, 4% mutation)
and PTEN (7% deletion, <1% mutation) of their HGS OC
cohort18. However, recent whole genome analysis of HGS OC
has  revealed  that  RB1  and  NF1  are  frequent  targets  of
previously unidentified gene breakage events, affecting 20%
and 17.5% of cases,  respectively,  underscoring the role of
large  structural  rearrangements  in  tumor  suppressor
inactivation in OC45.
Approximately 6% of HGS OC displays amplification of
the EMSY gene, which encodes a BRCA2-inhibiting protein
implicated in DNA repair regulation, as well as in chromatin
remodelling  and  wider  transcriptional  control61.  These
tumors are thought of as likely HRR-defective,  and it  has
therefore  been  suggested  that  EMSY-amplified  OC  may
respond well to PARPi therapy62. However, the question of
whether  these  tumors  are  truly  HRR-deficient  remains
controversial and the efficacy of PARPi use within this group
remains to be established.
Of the non-HRR-deficient HGS OC cases,  a  significant
proportion display amplification of CCNE1, encoding the cell
cycle checkpoint regulator cyclin E1. Approximately 14% of
HGS OC harbors this abnormality, which has been proposed
as a  novel  therapeutic  target18.  It  has been suggested that
CCNE1  amplification  and  BRCA1/2  dysfunction  occur
mutually  exclusively,  and thus CCNE1-targeted therapies
may represent a valuable treatment option in patients who
are  not  candidates  for  PARPi  therapy45,63.  Furthermore,
CCNE1  amplification  has  been  implicated  in  intrinsic
platinum resistance, and may represent a therapeutic target
for sensitization of disease that is intrinsically resistant to
cytotoxic agents45,64.
Gene expression
Because HGS represents the majority of OC, gene expression
 
Figure 1   Common molecular events identified in HGS OC, including genetic and epigenetic defects in HRR pathway components (right).
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studies  have  thus  far  largely  focussed  on  this  subgroup.
Indeed, HGS samples have dominated even mixed-histology
gene expression studies, owing to its high prevalence relative
to  other  histological  subgroups19.  Using  supervised  and
unsupervised analysis, these studies have been successful in
generating prognostic gene signatures and discrete molecular
subgroups, respectively18,19,65-71.
Tothill  et al.21  conducted unsupervised gene expression
analysis of nearly 300 OC cases, the majority of which were
HGS OC. They identified six molecular subgroups, termed
C1-C6, four of which (C1, C2, C4 and C5) accounted for
nearly all HGS samples. C2 tumors displayed high expression
of immune response-related genes, while C5 tumors showed
enrichment of genes expressed in mesenchymal development.
C1 tumors were characterized by high expression of stromal
genes and C4 were characterized by a low stromal response.
Multivariate survival analysis comparing C1 tumors versus
the other three HGS subgroups revealed that these patients
had  significantly  inferior  PFS  and  OS,  implicating  an
involvement of the stromal response in patient outcome.
Subsequent to the Tothill study, the Cancer Genome Atlas
(TCGA)  investigators  identified  four  transcriptionally-
defined groups within HGS OC18. These subgroups - termed
prol i ferat ive,  mesenchymal,  immunoreactive  and
differentiated - did not display significant survival differences
within the TCGA dataset, but recapitulation of these groups
in other datasets has shown clinical relevance, revealing a
survival advantage for those in the immunoreactive group66.
The TCGA immunoreactive and mesenchymal groups were
consistent with the Tothill C2 and C5 groups, respectively.
While a survival advantage for HGS OC with high levels of
immune activation is emerging, these subgrouping methods
are yet to be utilized clinically, and we await consensus on
molecular subgrouping of HGS OC that can ultimately be
taken forward into routine clinical practice.
Numerous  gene  expression  signatures  for  predicting
survival  in advanced stage OC have been produced using
supervised analyses of mRNA expression data from various
platforms.  These  signatures  have  been  produced  using
training datasets of varying numbers and many have proven
prognostic in independent datasets65-73. Among them is the
signature produced by the TCGA investigators, which has
validated in multiple datasets18.  However, performance of
these survival signatures varies between independent cohorts,
with poor correlation of risk scores between some studies,
and such signatures are yet to be used to inform OC patient
management72.
Heterogeneity
As  the  emergence  of  chemoresistant  recurrent  disease
represents  the  primary  cause  of  mortality  in  HGS  OC
patients, intratumor heterogeneity, facilitating selection of
pre-existing chemoresistant subclones during treatment, is of
great interest. Expansion of these clones represents an avenue
for  rapid  emergency  of  recurrent  disease  with  therapy
resistance74,75.  Such  intratumoral  heterogeneity  is  a
prominent feature in HGS OC76,77.  Indeed, quantitatively
assessment  of  intratumoral  heterogeneity  may  prove
clinically  informative in HGS OC, with patients  suffering
from highly heterogeneous disease showing shorter PFS and
OS78.
Existence  of  genetically  and  phenotypically  diverse
subclonal  populations  within  primary  HGS  disease  also
present a critical avenue for the failure of novel and existing
targeted therapies. Accordingly, the design of novel targeted
therapeutic strategies must be centered towards carcinogenic
driver  mutations  at  the  'trunk'  of  the  evolving  cancer
genome.
Molecular changes in acquired therapy
resistance in HGS OC
The  majority  of  HGS  OC  patients  have  a  good  clinical
response  to  primary  platinum-based chemotherapy.  As  a
result, characterizing mechanisms of acquired resistance in
the recurrent  disease  setting is  of  great  clinical  relevance.
Reversion of BRCA1  and BRCA2  mutations via secondary
genomic events that restore open reading frames, returning
HRR proficiency, has been proposed as one mechanism of
reducing  sensitivity  to  conventional  therapies45 ,79 .
Accordingly,  these  BRCA-reverted  tumors  may  well  also
show decreased sensitivity to targeted PARPi therapy.
Further  proposed  mechanisms  of  acquired  resistance
include  upregulation  of  AKT  signalling,  promoting  cell
survival, and increased expression of the ABCB1 drug efflux
protein via promoter hijacking45,80.  Paclitaxel,  commonly
used  in  combination  with  platinum  agents  in  first-line
treatment  of  OC,  is  a  known  substrate  of  ABCB1,  and
increased expression therefore represents a viable mechanism
for reduced accumulation of cytotoxic agents within ABCB1-
expressing OC cells81. These molecular events may well be
clinically actionable in the hope of re-sensitizing disease to
conventional  therapies,  although  modulation  of  ABCB1
activity  has  not  yet  proven  efficacious  in  advanced  stage
OC82.
While some mechanisms of therapy resistance have been
elucidated, identification of pathways involved in platinum-
resistant recurrent OC remains in its infancy and existing
studies  have  investigated  a  relatively  small  number  of
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relapsed disease samples45,79,80. Extensive characterization of
the molecular events underpinning subsequent treatment
failure have largely been hindered by the failure to acquire
multiple,  temporally  separated  biopsies  from  the  same
patient throughout the course of their disease. Investigation
of  large  cohorts  of  such paired samples  will  undoubtedly
uncover further mechanisms of acquired disease resistance
which  may  present  further  opportunities  for  therapeutic
intervention and re-sensitization of chemoresistant disease.
Epigenetic and microRNA dysregulation in
HGS OC
OC research thus far has largely been dominated by analyses
at the exomic sequence and transcriptional level. However,
progress  in  defining  the  epigenomic  and  microRNA
landscapes of OC has been made in recent years.
Promoter hypermethylation and associated gene silencing
of BRCA1 is perhaps the most canonical epigenetic defect in
HGS OC. While these tumors are considered HRR-deficient
and  this  molecular  event  appears  to  occur  mutually
exclusively  with  germline  or  somatic  BRCA1/2  mutation,
BRCA1-methylated patients may not experience the classical
BRCA-associated clinical benefit, as discussed above18,58,59.
Accordingly, this epigenetic defect may be of limited clinical
interest.
The  TCGA investigators  reported  over  150  genes  with
increased DNA methylation and associated reduction in gene
expression,  including  BRCA118.  Clustering  of  HGS  OC
samples within their dataset revealed four subtypes based on
differential methylation which overlapped significantly with
their transcriptionally-defined groups.
Further  to  DNA  methylation  analysis,  the  TCGA
investigators reported three HGS OC subtypes defined by
their differential microRNA expression profiles, with one of
these subtypes displaying superior OS18. Numerous studies
have now found associations between expression of specific
microRNAs and clinical parameters, including disease stage,
histological subtype and chemoresistance83-85.
Improved understanding of how miRNA and epigenomic
dysregulation  contribute  to  OC  tumorigenesis  will
undoubtedly further understanding of disease biology, and
may well reveal opportunities for therapeutic intervention.
Key future research foci for HGS OC
With characterization of HGS OC at the DNA sequence level
having made substantial advances, understanding the clinical
implications of each of these molecular events is a clear long
term research goal. In particular, the importance of NF1 and
RB1 disruption - whether by deletion, mutation or recently
identified gene breakage - are of great interest, as together
these represent a significant proportion (approximately one
third) of HGS OC.
While those patients with germline BRCA1  and BRCA2
mutations have been fairly  well  characterized in terms of
improved  sensitivity  to  platinum  and  efficacy  of  PARP
inhibitors, the clinical implications of genetic events in other
HRR pathway components - including EMSY amplification -
remain to be extensively investigated. Further consideration
of  BRCA1  and  BRCA2  defects  as  distinct  entities,  and
comparison with BRCA1  promoter hypermethylation, will
also help address whether all  HRR pathway abnormalities
convey equal clinical implication - although evidence thus far
would suggest  otherwise.  Because of  the relative  rarity  of
non-BRCA HRR pathway aberrations,  large retrospective
cohorts  of  molecularly  characterized  patients  with  rich
clinical annotation will be required.
A key step for future research will be to establish panels of
cell lines that represent the spectrum of molecular changes
that are now known to occur in HGS OC. This will provide
an invaluable pre-clinical  resource for investigating novel
therapeutic strategies in the context of underlying molecular
biology  of  disease,  and  will  likely  uncover  potential  new
biomarkers for sensitivity to both targeted and conventional
therapies.
The acquisition and molecular characterization of paired
chemosensitive primary and chemoresistant recurrent disease
specimens  represent  an  immediate  research  priority.
Sampling from recurrent disease, end stage disease and even
post-mortem sampling from rapid autopsy will undoubtedly
shed  more  l ight  upon  the  molecular  mechanisms
underpinning therapy-resistant recurrent disease, to which
patients ultimate succumb.
In  terms  of  transcriptional  profiling  of  HGS  OC,
significant  advances  have been made in finding clinically
relevant subgroups. Unsupervised analyses have identified
molecular  subgroups  with  distinct  clinical  outcomes  and
supervised  approaches  have  produced  gene  expression
signatures predictive of survival. However, a real consensus
in subgrouping remains to be established. Reproducibility
has  in  part  been hindered  by  limited  sample  numbers  in
training datasets  in some studies,  differential  histological
composition of datasets, as well as technical factors such as
the diversity of gene expression platforms used and the use of
fresh-frozen  versus  formalin-fixed  paraffin-embedded
(FFPE) tumor material. The culmination of these pitfalls is
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that molecular subgrouping is ultimately not currently used
to guide management of patients in the clinic. Demonstrating
subgroup-specific  actionable  molecular  biology and drug
sensitivities in the research setting will be a crucial step in
demonstrating the need for such stratification in the clinic.
Given  numerous  reports  of  the  impact  of  tumoral-
immune response on PFS and OS, understanding if and how
these above mentioned molecular features of OC influence
the interaction with the host immune system will also be of
interest86,87. Indeed, recent data have shown that BRCA1/2-
mutated  OCs  display  higher  levels  of  tumor-infiltrating
lymphocytes,  indicating  these  tumors  may  be  more
immunogenic,  consistent  with  the  survival  advantage
experienced by this patient group88. Such analyses may well
prove  informative  in  relation  to  the  efficacy  of  immune
checkpoint inhibitor therapy, and establishing biomarkers of
tumor immunogenicity may help stratify patients who are
likely to benefit from these, and other, immunotherapeutic
strategies.
Genetic and molecular changes in
non-HGS OC
Endometrioid, CC, LGS and mucinous subtypes account for
nearly  all  remaining OC cases,  representing around 10%,
10%, <5% and <5% of OC cases, respectively. These rarer
subtypes represent distinct disease entities from both HGS
OC and from one another. Collectively, and conversely to
HGS OC, they harbor activating oncogenic mutations more
typical of solid tumors but do not display high rates of TP53
mutation89,90.
Endometrioid OC
Of the OC histological subtypes, endometrioid OC represents
the group with most favorable clinical outcome: they have a
tendency to be diagnosed at earlier stage versus HGS OC and
are generally sensitive to platinum in the first line setting27,28.
Endometrioid OC is associated with endometriosis, and their
gene  expression  profiles  bear  resemblance  to  that  of
endometrial tissue9,16,91. Together, endometrioid and CC OC
represent the majority of  Lynch syndrome-associated OC
cases92-94.
Historically, endometrioid OC has been subclassified into
either  low  or  high  grade  disease.  However,  it  is  now
recognized that high grade endometrioid OC more closely
resembles HGS OC both molecularly and clinically, while low
grade  endometrioid  OC  represents  a  more  distinct  'true
endometrioid' OC subtype95.
Mutations deregulating the PI3K pathway are common in
this latter subtype: around 20% of cases harbor PTEN tumor
suppressor  gene  mutations  and  around  30%  display
activating  PIK3CA  mutations96-98 .  Around  30%  of
endometrioid  OC  displays  mutations  in  the  chromatin-
remodelling  associated  gene  ARID1A,  a  suggested  tumor
suppressor  gene99,100.  A  minority  also  harbor  somatic
mutations  in  the  PPP2R1A  gene,  encoding  a  subunit  of
protein phosphatase 2A101.
Endometrioid OC also commonly displays activated Wnt
s igna l l ing ,  wi th  around  ha l f  showing  CTNNB1
mutation96,97,102.
Clear cell OC
As with endometrioid ovarian cancer, CC OC is associated
with endometriosis and has a tendency to be diagnosed at
earlier  stage  versus  HGS  OC22,29,30.  However,  CC  OC
frequently  displays  intrinsic  platinum  resistance  and
advanced stage CC OC remains a  great  clinical  challenge,
with inferior PFS and OS compared to advanced stage HGS
OC22,30.  CC  OC  accounts  for  the  majority  of  non-
endometrioid  cases  associated  with  inherited  MMR
deficiency93,94.
Like endometrioid OC, CC carcinomas harbor defects in
PTEN (in around 10% of cases), PIK3CA (in around 50% of
cases),  and ARID1A  (in around 50% of cases),  consistent
with the shared molecular pathogenesis and developmental
origins of these carcinomas97,99,103-106. Similarly, a minority
display  somatic  PPP2R1A  mutation101.  However,  unlike
endometrioid  OC,  around  a  third  of  CC  tumors  show
amplification of  chr20q13.2  and do not  generally  harbor
Wnt-activating CTNNB1 mutations97,107.
Mucinous OC
Mucinous OC was once thought to account for a significant
number of OC cases, but it is now recognized that few are
true  primary  mucinous  OC,  while  the  rest  represent
metastases from other malignancies, most commonly from
the gastrointestinal  tract9,108.  In  comparison to  HGS OC,
mucinous  OC  tends  to  present  at  earlier  stage109,110.
However,  this  subtype  frequently  displays  platinum
resistance  in  the  first  line  setting,  and  advanced  stage
mucinous OC is associated with particularly poor OS24,111.
The  molecular  pathogenesis  of  mucinous  OC  remains
relatively poorly understood, and extensive characterization
of  this  subtype  has  largely  been  hindered  by  its  low
prevalence  compared  to  other  histological  OC  subtypes.
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However, KRAS mutation and HER2 gene amplification are
known common events in mucinous OC, with around 50%
and 20% of cases displaying these defects, respectively109,112.
LGS OC
LGS OC is characterized by young age at diagnosis, indolent
disease  course,  and  prolonged  OS  versus  HGS  OC,  even
when diagnosed at advanced stage25. Over 60% of LGS OC
harbor MAPK pathway-activating KRAS or BRAF mutations,
accounting  for  around  30%  of  cases  each,  but  almost
invariably do not harbor TP53 mutations113-115. Furthermore,
KRAS  mutation  may  be  associated  with  more  aggressive,
recurrent disease versus BRAF-mutated LGS OC116,117.
Key future research foci for non-HGS OC
Recognition of  non-HGS OC subtypes  as  distinct  disease
entities  has  been a critical  step in OC research.  Although
mucinous,  CC and endometrioid  OC is  more  commonly
diagnosed at early stage versus HGS OC, advanced stage cases
present  a  significant  clinical  challenge22,27-30,111.  Clinical
studies  now  need  to  be  performed  in  a  subtype-specific
fashion  in  order  to  properly  characterize  the  underlying
biology within each of these histotypes at both the genomic
and transcriptional level.
In  particular,  the  characterization  of  non-HGS  OC
subtypes  that  display  resistance  to  the  platinum-based
chemotherapies  are  needed,  as  these  agents  remain  a
cornerstone  of  OC  treatment  irrespective  of  histological
subtype. These studies hope to uncover underlying disease
biology that may be actionable through the use of novel or
existing  targeted  therapies,  with  the  aim  of  improving
treatment either directly through selective cytotoxicity or
indirectly  through  sensitizing  disease  to  conventional
therapies.
Our current understanding of the biology behind these
rarer  subtypes  has  already revealed  avenues  for  potential
implementation of targeted therapies: LGS and mucinous OC
may well benefit from MAPK pathway inhibitors, while CC
and endometrioid OC may benefit from agents targeting the
PI3K pathway. Indeed, the MEK1/2 inhibitor selumetinib has
shown  promising  results  in  patients  with  recurrent  LGS
OC118.  Targeting  HER2  has  already  proven  a  successful
treatment strategy in HER2-amplified breast cancer, and the
use  of  therapies  such  as  the  monoclonal  antibody
trastuzumab  may  also  prove  useful  in  treating  HER2-
amplified  mucinous  OC119.  Investigating  the  potential
therapeutic efficacy of these and other agents in genomically
characterized  disease  models  will  be  an  important  step
toward therapy stratification within these rarer OC subtypes.
Perhaps the greatest challenge for single-histotype studies
of non-HGS OC will be acquiring large cohorts of these rarer
subtypes.  Historic  samples  will  need to undergo rigorous
pathology  review  to  ensure  the  accuracy  of  histotype
assignment. Sample numbers will be a particular challenge
for  studies  looking  to  identify  transcriptionally-defined
molecular  subgroups  by  unsupervised  analysis,  as  these
investigations  will  require  large  training  and  validation
cohorts.  Indeed,  acquiring  uniformly  staged,  graded  and
treated  cohorts  of  OC  remains  a  challenge  even  in  HGS
disease.
Conclusions
OC is a substantial cause of morbidity and mortality in the
developed world. A number of clinical features are known to
affect PFS and OS rates in OC, including disease stage, grade
and surgical outcome. The five main histologically-defined
subtypes of OC are now recognized as separate diseases and
display  differences  in  stage  at  diagnosis,  responses  to
platinum-based chemotherapies as well as OS.
However, substantial clinical heterogeneity remains even
within these histological  groups,  particularly  within HGS
which represents the majority of OC. As such, the majority of
the  research  effort  thus  far  has  focused  on  this  subtype,
elucidating  clinically  meaningful  subgroups  at  both  the
genomic and transcriptomic level, despite extreme genomic
heterogeneity. The challenge remains for these subgroups to
be taken forward into the clinic, and we await a consensus on
clinically meaningful transcriptomic subgroups that validate
in the wealth of publicly available HGS OC gene expression
data.  At  present,  only  BRCA  status  is  routinely  used
clinically, with germline BRCA1 and BRCA2 genetic testing
now in place at a number of centers as a biomarker for the
use  of  PARPi  therapy.  Rarer  genomic  defects  in  HRR
pathway components remains an area of great interest, and
the field awaits data on whether these patients are truly HRR
deficient and likely to benefit from PARP inhibition.
The  clinical  implications  of  more  recently  identified
genomic defects, including NF1 and RB1 loss, remain to be
established.  Together  with  CCNE1  amplification,  these
defects account for much of HRR-proficient HGS OC, and
finding  novel  therapeutic  strategies  to  improve  clinical
outcome in these patients is  an area of  substantial  unmet
need.
Recurrent HGS OS with acquired chemoresistance is the
ultimate cause of the majority of patient mortality. Therefore,
242 Hollis et al. Genetic and molecular changes in ovarian cancer
investigating  its  molecular  drivers  is  an  urgent  research
priority. The acquisition and molecular characterization of
matched primary and recurrent samples promise to reveal
opportunities for using novel therapeutic strategies and re-
sensitizing to cytotoxic agents.
Non-HGS OC is characterized by more classical oncogenic
mutations, and subtype-specific studies of endometrioid, CC,
LGS and mucinous OC are now needed to further stratify
these subtypes at both the transcriptomic and genomic level.
The real challenge for these investigations will be acquiring
sufficiently large cohorts to make meaningful conclusions
that can pave the way for stratification of therapy, which will
undoubtedly require international collaborative efforts.
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